Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to ...

Rajesh Kumar, HSBC's head of life sciences and healthcare research, discusses the key concerns facing anti-obesity drug ...

The biotech company extends its Phase I trial (NCT06252220) of DA-1726 to eight weeks following encouraging early efficacy, ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion. Sales increased due to an 8.5% increase in revenue ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions ...

HealthDay News — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with the risk of developing nonarteritic anterior ischemic optic ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...